Core Viewpoint - The company, Hefei China (603122.SH), has signed a long-term procurement agreement with Nanjing Mingji Hospital and Suzhou Mingji Hospital for the supply of in vitro diagnostic reagents and consumables, with a total procurement amount of no less than RMB 600 million over 96 months [1] Group 1 - The agreement stipulates that Mingji Hospital will purchase in vitro diagnostic reagents and consumables from the company [1] - The total procurement amount is set at a minimum of RMB 600 million over a period of 96 months [1] - The company will also provide corresponding comprehensive services as part of the agreement [1]

格隆汇1月25日丨合富中国(603122.SH)公布，经财务部门初步测算，预计2025年年度归属于母公司所有 者的净利润为-3,600万元到-2,500万元，与上年同期（法定披露数据）相比，将出现亏损。预计2025年 年度实现归属于母公司所有者的扣除非经常性损益后的净利润为-3,500万元到-2,400万元。 ...

Core Viewpoint - The company, Hefei China, anticipates a significant net loss for the year 2025, with projected losses ranging from 25 million to 36 million yuan for net profit attributable to shareholders, and from 24 million to 35 million yuan for net profit after excluding non-recurring gains and losses [1] Group 1: Financial Performance - The expected net loss for 2025 is between 25 million and 36 million yuan [1] - The projected net profit after excluding non-recurring items is estimated to be between 24 million and 35 million yuan [1] Group 2: Reasons for Performance - The primary reasons for the anticipated losses include changes in the domestic macro environment and the impact of centralized procurement policies in the in-vitro diagnostic industry, leading to decreased product procurement prices and fluctuations in order volumes [1] - Despite cost-saving measures, fixed expenditures could not be proportionately reduced alongside income, and investments in talent optimization and capability upgrades contributed to the expected losses [1] - The company is actively adjusting its business layout and development strategy, focusing on the technological iteration and innovation of its proprietary "ACME" products, increasing R&D investments, and expanding its market development team [1]

证券代码：603122 证券简称：合富中国 公告编号：临 2026-003 合富（中国）医疗科技股份有限公司 关于签订日常经营重大合同的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、《上海证券交易所股票上市规则》6.2.2 款要求"合同金额占上市公司 最近一期经审计主营业务收入 50%以上，且绝对金额超过 5 亿元，应及时披露"。 合富（中国）医疗科技股份有限公司（以下简称"公司"）与南京明基医院、苏 州明基医院（以下合称"明基医院"）签订了《长期采购协议》（以下简称"合 同"）。明基医院在 96 个月内采购总金额不低于人民币 6.00 亿元。合约约定如 采购期限内体外诊断试剂及耗材中标价格或项目收费调整，则公司的供应价格应 当同比例调整，价格生效日追溯至政府或明基医院当地采购平台调价文件公布之 日，如导致未能达到约定的最低采购金额，公司与明基医院将另行协商解决方案。 2、本次合同为公司日常经营合同，履约时间较长，预计明基医院每年采购 金额低于公司年度收入的 10%，对公司每年业绩的影响较小，不会出 ...

每经AI快讯，1月25日，合富中国（603122）发布2025年年度业绩预告，预计归属于上市公司股东的净 利润为-3600万元到-2500万元，与上年同期相比将出现亏损。业绩变动原因：受集采政策影响，客户采 购价格下降、订单波动，叠加人员优化与能力升级投入及研发投入增加。 ...

证券代码：603122 证券简称：合富中国 公告编号：临 2026-004 合富（中国）医疗科技股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 业绩预告的具体适用情形：净利润为负值。 经财务部门初步测算，合富（中国）医疗科技股份有限公司（以下简称 "公司"）预计 2025 年年度归属于母公司所有者的净利润为-3,600 万元到 -2,500 万元，与上年度（法定披露数据）相比，将出现亏损。 一、本期业绩预告情况 （一）业绩预告期间 预计 2025 年年度实现归属于母公司所有者的扣除非经常性损益后的净利润 为-3,500 万元到-2,400 万元。 二、上年同期经营业绩和财务状况 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 经财务部门初步测算，预计 2025 年年度归属于母公司所有者的净利润为 -3,600 万元到-2,500 万元，与上年同期（法定披露数据）相比，将出现亏损。 （一）利润总额：3,946.67 万元。归属于母公司 ...

格隆汇1月25日｜合富中国公告，预计2025年年度净利润为负值，预计在-3600万元到-2500万元之间。 预计2025年年度实现归属于母公司所有者的扣除非经常性损益后的净利润为-3500万元到-2400万元。 ...

合富中国公告称，预计2025年年度归属于母公司所有者的净利润为-3600万元到-2500万元，上年同期为 2756.63万元；扣非净利润为-3500万元到-2400万元，上年同期为2610.97万元。业绩预亏主因是行业政 策调整，产品采购价下降、订单规模波动，且固定支出未同额减少，人员优化升级有投入，研发投入也 在增加。预告数据未经审计，具体以年报为准。 ...

Core Viewpoint - The A-share market for pharmaceutical retail stocks experienced a collective rise, driven by new government measures aimed at enhancing pharmaceutical services and encouraging retail drug sales [1] Group 1: Market Performance - Pharmaceutical retail stocks such as Renmin Tongtai and Yifeng Pharmacy hit the daily limit up, while Luyuan Pharmaceutical rose over 7%, Daclin increased over 6%, and Jiuzhoutong gained over 5% [1] - Other notable performers included Zhongyao Holdings, Yaoyigou, Haiwang Biological, Hefuchina, and Shuyupingmin, all rising over 4% [1] Group 2: Government Measures - The Ministry of Commerce and nine other departments issued a document proposing improvements in pharmaceutical services, enhancing pharmacy service capabilities, and promoting prescription circulation to improve the purchasing experience [1] - Measures include optimizing outpatient service coordination for designated retail pharmacies and encouraging retail drug companies to participate in centralized drug procurement [1] - The government is promoting horizontal mergers and acquisitions among retail drug companies and encouraging the sale of innovative drugs and reference preparations through retail channels [1] - There is an emphasis on encouraging e-pharmacy platforms to open data interfaces and strengthen the monitoring of price linkages between online and offline drug retail prices and provincial procurement platform prices [1]

Group 1 - The core viewpoint of the article highlights a collective rise in A-share pharmaceutical commercial stocks, driven by government initiatives to enhance pharmaceutical services and retail drug sales [1] - The Ministry of Commerce and nine other departments issued a document proposing measures to improve pharmaceutical services, enhance pharmacy service capabilities, and promote prescription circulation to improve the purchasing experience [1] - The document encourages pharmaceutical retail companies to engage in horizontal mergers and acquisitions, and to innovate in drug sales channels, including the sale of innovative drugs and reference preparations through retail pharmacies [1] Group 2 - Notable stock performances include: - Renmin Tongtai (人民同泰) with a rise of 10.04% and a total market value of 72.43 billion [2] - Yifeng Pharmacy (益丰药房) increasing by 10.02% with a market cap of 301 billion [2] - Luyuan Pharmaceutical (鹭燕医药) up by 7.76% with a market value of 70.13 billion [2] - Dacelin (大参林) rising by 6.63% with a market cap of 242 billion [2] - Jiuzhoutong (九州通) increasing by 5.27% with a market value of 282 billion [2] - Other companies showing significant gains include Zhongyao Holdings (重药控股) up by 4.89%, Yaoyigou (药易购) up by 4.42%, and Haiwang Biological (海王生物) up by 4.41% [2]